PCM
CRSP icon

Pathway Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Pathway Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,049
Closed -$3.24M – 7
2025
Q3 		$3.24M Buy
+50,049
New +$2.87M 15.95% 4

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathway Capital Management's CRSP Position: Q4 2025 in Review

Pathway Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 50,049 shares — an estimated $3.24M sold.

Pathway Capital Management first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $3.24M in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Pathway Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pathway Capital Management sold 50,049 CRISPR Therapeutics shares in Q4 2025, an estimated $3.24M.
  • Pathway Capital Management first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • Pathway Capital Management's CRISPR Therapeutics position peaked at $3.24M in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Pathway Capital Management's 13F filing for Q4 2025, filed 4 Feb 2026.